A non-randomised study investigating the use and timing of multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) to develop imaging biomarkers that will be used to predict treatment response following radiotherapy for prostate cancer treatment.
- Conditions
- Prostate CancerCancer - Prostate
- Registration Number
- ACTRN12618001810202
- Lead Sponsor
- niversity of Sydney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 30
Biopsy proven localised prostate cancer.
Great than or equal to 18 years of age.
Willing and able to comply with all study requirements.
Signed, written and informed consent.
Completed MRI safety screening as per local policy.
Up to 4 months ADT prior to radiotherapy.
No more than 20 participants who receive ADT.
Mentally impaired participants or participants for who obtaining informed consent would be difficult.
Unable to undergo an MRI examination or has contraindications to MRI.
Inadequate renal function for contrast administration (eGFR <60 ml/min) at baseline imaging.
Participants who have been clinically diagnosed with severe claustrophobia.
Prior pelvic radiotherapy.
Any prosthetic implants such as metallic hip prostheses that may cause artefacts in the imaging studies.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method